Kennedy Trust for Rheumatology Research v. Hospira Healthcare Corporation, 2020 FCA 31 (Infliximab*)
Justice Nadon; Justice Locke; Justice Rivoalen - 2020-01-30
Read full decision. Automatically generated summary:
Because of our conclusion in court file A-338-18 (2020 FCA 30) that the judgment of the Federal Court dated September 28, 2018 (2018 FC 259) must be set aside, including the order of costs in favour of the respondents contained therein, it follows that the Federal Court’s Order of October 23, 2018 (2018 FC 1067), as amended by an Order dated January 21, 2019, fixing the respondents costs at the sum of $3,481,778.54, must also be set aside.
Decision relates to:
- A-354-18 - HOSPIRA HEALTHCARE CORP. v. KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH which is an appeal from 2018 FC 1067 in T-396-13
- A-360-18 - HOSPIRA HEALTHCARE CORPORATION v THE KENNEDY TRUST FOR RHEUMATOLOGY RESEARCH which is an appeal from a decision dated 2018-10-30 in T-396-13